Is the RSV Vaccine Safe During Pregnancy? What Expecting Parents Need to Know

Quick take: The RSV vaccine during pregnancy is a safe and effective way to protect your newborn from severe respiratory syncytial virus (RSV) infection. Recommended by the CDC, a single dose given in the third trimester helps transfer protective antibodies to your baby, offering crucial immunity during their most vulnerable first months of life. Talk to your healthcare provider to discuss if it's right for you during the upcoming RSV season.

As an expectant parent, navigating all the decisions for your baby's health can feel overwhelming. You want to give them the best start possible, and that often means protecting them even before they arrive. One significant concern for many parents, especially during the colder months, is Respiratory Syncytial Virus (RSV) — a common respiratory virus that can be particularly dangerous for infants.

You might have heard about the new RSV vaccine and wondered if it's something you should consider during pregnancy. The good news is that medical science has made incredible strides in offering protection. The Centers for Disease Control and Prevention (CDC) now recommends a maternal RSV vaccine for pregnant individuals to help safeguard their newborns. This article will walk you through everything you need to know about getting the RSV vaccine during pregnancy, from its safety and benefits to timing and how it works.

We understand you have questions, and we're here to provide clear, evidence-based answers to help you make an informed decision for yourself and your little one.

Is the RSV vaccine safe for pregnant women and their babies?

The safety of any vaccine during pregnancy is, understandably, a top concern for expectant mothers. When it comes to the RSV vaccine, extensive research and careful monitoring have shown it to be safe for both pregnant women and their developing babies. This maternal RSV vaccine (marketed as Abrysvo) underwent rigorous clinical trials involving thousands of pregnant individuals and their infants before receiving approval from the U.S. Food and Drug Administration (FDA) in August 2023.

These clinical trials specifically looked for any adverse effects on the mother, such as serious allergic reactions, and on the baby, including preterm birth, low birth weight, or congenital anomalies. The data consistently demonstrated a favorable safety profile. The most common side effects observed were mild to moderate and similar to those seen with other vaccines, such as soreness at the injection site.

Following FDA approval, the CDC's Advisory Committee on Immunization Practices (ACIP) reviewed all available data and also recommended the vaccine for pregnant individuals. This recommendation is a strong endorsement of the vaccine's safety and effectiveness. Regulatory bodies like the FDA and CDC have very high standards for vaccines administered during pregnancy, recognizing the importance of protecting both mother and child without causing harm.

It’s important to remember that the vaccine does not contain live virus particles; instead, it uses a portion of the RSV virus's outer protein to teach your immune system how to recognize and fight RSV. This means there is no risk of the vaccine causing an RSV infection in you or your baby.

What do clinical trials say about the RSV vaccine's safety?

The primary clinical trial that led to the approval of the maternal RSV vaccine was a large, international, placebo-controlled study called MATISSE. This study enrolled approximately 7,400 pregnant individuals and their infants. Participants were randomly assigned to receive either the RSV vaccine or a placebo.

Researchers closely monitored both groups for any adverse events. The findings showed that the vaccine was well-tolerated. While there was a slight numerical increase in preterm births in the vaccine group compared to the placebo group in the initial data, further analysis and subsequent monitoring by the FDA and CDC determined that this difference was not statistically significant and was not directly attributable to the vaccine. Both the FDA and CDC continue to monitor vaccine safety closely through systems like the Vaccine Adverse Event Reporting System (VAERS) and the Vaccine Safety Datalink (VSD).

The overall consensus from leading health organizations, including the American College of Obstetricians and Gynecologists (ACOG), is that the benefits of preventing severe RSV disease in infants far outweigh the minimal and largely theoretical risks associated with the vaccine. Your healthcare provider will always weigh these factors and discuss any individual concerns you might have.

When is the best time to get the RSV vaccine during pregnancy?

T

This process of transferring antibodies typically takes about two weeks after vaccination. By vaccinating in the late third trimester, your baby is born with a robust level of passive immunity, protecting them from severe RSV disease right from birth and through their first few months of life, which is when they are most vulnerable to serious complications from the virus.

The RSV season typically runs from fall through spring, with peaks often occurring in winter. Therefore, healthcare providers generally administer the vaccine to pregnant individuals during this seasonal window. If you are pregnant during the RSV season and are within the 32 to 36-week gestational window, your provider will likely recommend getting vaccinated. If you are outside of this window or the RSV season, your provider will discuss the best approach for protecting your baby, which might include considering nirsevimab (Beyfortus) for your infant after birth.

Why the third trimester for maternal RSV vaccination?

The selection of the 32 to 36-week gestational window for the RSV vaccine is strategic. During this period, the placenta is highly efficient at transferring antibodies from the mother to the fetus. This maternal antibody transfer is a natural protective mechanism, and vaccines like the RSV vaccine leverage this process to provide passive immunity to the newborn.

If the vaccine is given too early in pregnancy, the antibody levels in the baby might wane before they reach their most vulnerable period. If given too late (e.g., very close to delivery), there might not be enough time for the mother's immune system to produce a sufficient number of antibodies and for those antibodies to cross the placenta effectively. The 32 to 36-week window optimizes both the quantity and duration of antibody transfer, ensuring your baby has strong protection through their first six months of life.

It’s essential to discuss your specific timing with your healthcare provider. They will review your due date and the current RSV season activity to determine the optimal time for your vaccination. Don't hesitate to ask questions about the schedule and how it fits with any other vaccinations you might need during pregnancy, such as the Tdap or flu shot.

What are the benefits of the RSV vaccine for newborns?

The primary goal of getting the RSV vaccine during pregnancy is to protect your newborn baby from severe RSV infection. For infants, especially those under six months of age, RSV can be much more than just a common cold. It can lead to serious respiratory illnesses like bronchiolitis (inflammation of the small airways in the lungs) and pneumonia. These conditions often require hospitalization, oxygen support, and in rare cases, can be life-threatening.

By receiving the RSV vaccine during pregnancy, you pass on powerful antibodies to your baby. These antibodies act as a shield, helping your baby's immune system fight off RSV if they are exposed to the virus. This passive immunity is incredibly valuable because newborns have immature immune systems and cannot develop their own robust response to viruses like RSV as effectively as older children or adults.

Clinical trials have shown remarkable efficacy of the maternal RSV vaccine in preventing severe outcomes in infants. For example, the MATISSE study demonstrated that the vaccine was approximately 81.8% effective against severe RSV lower respiratory tract disease (LRTD) requiring medical attention within 90 days after birth, and 69.4% effective within 180 days after birth. This means a significantly reduced risk of your baby needing to see a doctor, visit the emergency room, or be hospitalized due to RSV.

How does maternal RSV vaccination prevent severe illness and hospitalizations?

The protection your baby receives from your RSV vaccination is a prime example of passive immunity. When you get the vaccine, your immune system creates antibodies specifically designed to neutralize the RSV virus. These antibodies are then transferred through the placenta to your baby in utero. Once born, your baby carries these maternal antibodies, which are ready to spring into action if they encounter the RSV virus.

When an unvaccinated infant is exposed to RSV, their developing immune system might struggle to mount an effective defense, allowing the virus to replicate rapidly and cause significant inflammation in their tiny airways. This can lead to difficulty breathing, wheezing, and congestion, often necessitating medical intervention.

However, for a baby born with maternal RSV antibodies, these antibodies can quickly bind to the virus, preventing it from infecting cells and multiplying. This either prevents the infection entirely or significantly reduces the severity of the illness, turning what could have been a serious hospitalization into a milder, manageable cold-like illness. This protection is especially crucial during the first six months of life when infants are at the highest risk for severe RSV outcomes.

Beyond the direct health benefits for your baby, there's also the peace of mind for you as a parent. Knowing you've provided this critical early protection can alleviate much of the anxiety associated with your baby's first RSV season. It also contributes to public health by reducing the burden on healthcare systems during peak RSV times.

Are there any side effects of the RSV vaccine for pregnant women?

Like any vaccine, the RSV vaccine can cause side effects, but these are generally mild to moderate and temporary. The most commonly reported side effects are similar to those experienced with other routine vaccines, such as the flu shot or Tdap vaccine. You might feel a bit under the weather for a day or two, but serious reactions are rare.

Common side effects you might experience

• Pain, swelling, or redness at the injection site: This is the most common side effect and usually resolves within a day or two. Applying a cool compress can help.
• Fatigue: Feeling tired or run down for a day or two after the shot is normal.
• Headache: A mild headache can occur.
• Muscle aches: You might experience some generalized body aches.
• Nausea: Some individuals report mild nausea.

These side effects are a sign that your immune system is responding to the vaccine and building protection. They are typically short-lived and do not require specific treatment beyond over-the-counter pain relievers like acetaminophen (which is generally safe during pregnancy, but always check with your doctor). If you experience any severe or persistent symptoms, or if you have concerns, contact your healthcare provider.

Rare and serious side effects

Serious allergic reactions (anaphylaxis) are extremely rare but can occur with any vaccine. This is why you are typically asked to wait at the clinic for 15-20 minutes after vaccination, so medical staff can monitor you for any immediate reactions. Symptoms of a severe allergic reaction include difficulty breathing, swelling of the face and throat, a rapid heartbeat, or a generalized rash.

As mentioned earlier, initial clinical trial data showed a numerical increase in preterm births in the vaccine group compared to the placebo group. However, extensive review by the FDA and CDC, along with ongoing surveillance, has concluded that this observation was not statistically significant and a causal link between the vaccine and preterm birth has not been established. The overall safety profile remains favorable, and the benefits of preventing severe RSV in infants are considered to outweigh these theoretical concerns.

There are very few contraindications for the RSV vaccine during pregnancy. It is generally not recommended if you have a history of a severe allergic reaction to any component of the vaccine. Always disclose your full medical history and any allergies to your healthcare provider before vaccination.

How does the RSV vaccine protect my baby from RSV infection?

The RSV vaccine works by preparing your immune system to fight the virus, and then leveraging your body's natural ability to pass on immunity to your baby. It's a fascinating example of how maternal vaccination provides what's known as "passive immunity."

Here's a step-by-step breakdown of how this protection unfolds:

1. Vaccine Administration: You receive a single injection of the RSV vaccine, typically in your arm, during your third trimester (between 32 and 36 weeks of gestation).
2. Immune Response in You: The vaccine contains a specific protein from the RSV virus (called the F protein) that is crucial for the virus to infect human cells. This protein is presented in a way that stimulates your immune system without causing illness. Your body recognizes this protein as foreign and begins to produce specialized antibodies designed to neutralize it.
3. Antibody Transfer Across the Placenta: As your body generates these RSV-specific antibodies, they are transported across the placenta to your developing baby. This is a natural process that occurs throughout pregnancy, especially in the later stages, where your body shares its immune defenses with your fetus.
4. Baby Born with Protection: When your baby is born, they already have a significant level of these maternal RSV antibodies circulating in their bloodstream. These antibodies act as a pre-made defense system.
5. Protection Against Exposure: If your newborn is exposed to the RSV virus in their environment (which is very common), these circulating antibodies can quickly recognize the virus, bind to its F protein, and prevent it from effectively infecting cells in their respiratory tract. This either prevents the infection altogether or significantly reduces its severity.

This protective shield is particularly important during your baby's first six months of life, as their own immune system is still maturing and less capable of mounting a strong defense against serious infections like RSV. The maternal RSV vaccine provides critical protection when your baby is most vulnerable.

How long does RSV vaccine protection last for baby?

The protection conferred by the maternal RSV vaccine is designed to last through your baby's most vulnerable period. Clinical studies have shown that the antibodies transferred from you to your baby provide significant protection against severe RSV lower respiratory tract disease for at least six months after birth. This covers the typical duration of the RSV season for most infants born during or just before it.

After six months, the levels of maternal antibodies naturally start to decline. By this age, your baby's immune system is also becoming more developed and better equipped to handle respiratory viruses. However, the initial six months are crucial for preventing the most serious outcomes, such as hospitalization and intensive care admissions.

This duration of protection is a key factor in the CDC's recommendation, ensuring that infants are safeguarded during the time when they are at highest risk for severe RSV complications.

Who is recommended to get the RSV vaccine while pregnant?

The CDC's Advisory Committee on Immunization Practices (ACIP) provides clear guidance on who should receive the RSV vaccine during pregnancy. The recommendation is broad and inclusive:

All pregnant individuals should receive a single dose of the maternal RSV vaccine between 32 and 36 weeks of gestation during RSV season.

This recommendation is primarily aimed at protecting the newborn from severe RSV disease. It's not limited to those with specific risk factors, as all infants are susceptible to RSV, and severe cases can occur even in full-term, healthy babies. The goal is to provide widespread protection to the youngest and most vulnerable population.

The "RSV season" typically refers to the period of increased RSV activity in the community, which usually begins in the fall and extends through the winter and early spring. Your healthcare provider will be aware of the local RSV season patterns and will guide you on the optimal timing for your vaccination.

What if I have a high-risk pregnancy?

If you have a high-risk pregnancy, discussing all vaccination options with your healthcare provider is even more critical. However, the recommendation for the RSV vaccine is generally universal for all pregnant individuals within the specified gestational window and during RSV season. Conditions that might classify a pregnancy as high-risk (e.g., gestational diabetes, pre-eclampsia, carrying multiples) do not typically contraindicate the RSV vaccine. In fact, ensuring your baby receives passive immunity might be even more beneficial if there are any concerns about their overall health post-delivery.

It's important to note that the vaccine is approved for use in full-term and preterm births. The goal is to get those antibodies transferred. If there are specific concerns related to your individual health or pregnancy complications, your OB/GYN or maternal-fetal medicine specialist will provide personalized guidance. However, for the vast majority of pregnant individuals, the RSV vaccine is a recommended and safe intervention to protect their baby.

Can I get the RSV vaccine with other vaccines during pregnancy?

Yes, in most cases, the RSV vaccine can be co-administered with other recommended vaccines during pregnancy, such as the Tdap (tetanus, diphtheria, and pertussis) vaccine and the flu shot. The CDC and ACOG generally state that inactivated vaccines (which do not contain live virus, like the RSV, Tdap, and flu vaccines) can be given at the same visit or at any interval between doses.

Combining vaccines reduces the number of appointments needed and ensures you receive timely protection. Your healthcare provider will help you plan your vaccination schedule to ensure optimal timing for each vaccine, especially considering the specific gestational window for the RSV vaccine.

What is the difference between RSV vaccine and nirsevimab (Beyfortus) for babies?

It can be confusing to hear about two different ways to protect babies from RSV: the maternal RSV vaccine and a monoclonal antibody product called nirsevimab (Beyfortus). While both aim to prevent severe RSV disease in infants, they work differently and are intended for different situations.

Maternal RSV Vaccine (e.g., Abrysvo)

• Mechanism: This is a vaccine given to the pregnant parent. It stimulates the pregnant person's immune system to produce antibodies against RSV.
• Protection Method: These antibodies are then transferred across the placenta to the fetus, providing the baby with passive immunity at birth.
• Who Receives It: Pregnant individuals between 32 and 36 weeks of gestation during RSV season.
• Benefit: Protects the baby from birth through their first 6 months of life by providing pre-existing maternal antibodies.
• Type: Active immunization for the mother, resulting in passive immunity for the baby.

Nirsevimab (Beyfortus)

• Mechanism: This is a monoclonal antibody product given directly to the infant. It's not a vaccine in the traditional sense, as it doesn't stimulate the baby's immune system to produce its own antibodies. Instead, it *is* the antibodies.
• Protection Method: Provides immediate, direct protection through a pre-formed antibody that helps fight RSV.
• Who Receives It: Infants and young children, typically those born during or entering their first RSV season, and some high-risk children entering their second RSV season. It is administered as a single injection before or during the RSV season.
• Benefit: Provides immediate protection against RSV for about 5-6 months.
• Type: Passive immunity for the baby through direct administration of antibodies.

Here's a comparison table to highlight the key differences:

Can a baby receive both?

The CDC's recommendation is to provide protection through *one* of these methods, not both, for most infants. If a pregnant individual receives the RSV vaccine, their baby typically will not need nirsevimab because they are already protected by the maternal antibodies. However, if a pregnant individual did not receive the RSV vaccine (e.g., due to timing, personal choice, or not being pregnant during RSV season), then nirsevimab is recommended for their baby.

There are some specific circumstances where a baby might benefit from nirsevimab even if the mother was vaccinated, such as if the mother was vaccinated very close to delivery and there wasn't enough time for antibody transfer, or if the baby is born very preterm. Your pediatrician will assess your baby's individual needs and your vaccination history to determine the best course of action for RSV protection.

Myth vs. Fact

When new vaccines are introduced, it's natural for questions and misconceptions to arise. Let's clear up some common myths about the RSV vaccine during pregnancy.

Myth: The RSV vaccine is too new, so we don't know enough about its long-term safety for babies.

Fact: While the maternal RSV vaccine was recently approved, it underwent extensive and rigorous clinical trials involving thousands of pregnant individuals and their infants, with follow-up periods designed to assess safety. Regulatory bodies like the FDA and CDC approved it only after thorough review of its safety and efficacy data. Ongoing surveillance systems continue to monitor its safety in real-world use. The science behind maternal immunization, where antibodies are passed to the baby, is also well-established with other vaccines like Tdap and flu.

Myth: Getting the RSV vaccine while pregnant means my baby can't get RSV.

Fact: No vaccine offers 100% protection, and the RSV vaccine is no exception. However, it is highly effective at preventing *severe* RSV disease, hospitalization, and medically attended lower respiratory tract infections in infants. This means your baby might still get RSV, but if they do, the infection is much more likely to be mild, similar to a common cold, rather than leading to serious complications requiring emergency care or hospitalization. The goal is to reduce the burden of severe disease, not eliminate every single infection.

Myth: The RSV vaccine is mandatory for pregnant women.

Fact: The RSV vaccine is recommended by the CDC for pregnant individuals within a specific gestational window and during RSV season; it is not mandatory. Like other recommended vaccines during pregnancy (such as Tdap and the flu shot), it is a choice you make in consultation with your healthcare provider. The recommendation is based on strong evidence of its benefits in protecting your baby, but the decision ultimately rests with you after discussing the risks and benefits with your doctor.

Key Takeaways

• The maternal RSV vaccine is a safe and effective way to protect your newborn from severe RSV infection.
• It is recommended for pregnant individuals between 32 and 36 weeks of gestation during RSV season.
• The vaccine works by allowing you to transfer protective antibodies to your baby across the placenta.
• This passive immunity significantly reduces your baby's risk of severe RSV disease, hospitalization, and medically attended lower respiratory tract infection during their first six months.
• Common side effects are mild and temporary, similar to other vaccines, such as soreness at the injection site.
• The maternal RSV vaccine is distinct from nirsevimab (Beyfortus), which is a monoclonal antibody given directly to the infant. Generally, one or the other is recommended, not both.

Frequently Asked Questions

Is the RSV vaccine new for pregnant women?

Yes, the maternal RSV vaccine (Abrysvo) was approved by the FDA in August 2023 and subsequently recommended by the CDC for use in pregnant individuals. While RSV vaccines have been in development for many years, this specific vaccine for pregnant women to protect their infants is a recent and significant advancement in public health.

How much does the RSV vaccine cost for pregnant women?

The cost of the RSV vaccine for pregnant women can vary depending on your insurance coverage. Most private insurance plans, as well as Medicaid and Medicare, are expected to cover the cost of the vaccine under the Affordable Care Act's preventive services mandate. It's always best to check with your specific insurance provider or the clinic where you plan to get vaccinated to understand any potential out-of-pocket costs.

What happens if I get RSV while pregnant?

If you contract RSV while pregnant, it typically presents as a mild respiratory illness, similar to a common cold, with symptoms like runny nose, sore throat, cough, and fever. Most pregnant individuals recover without complications. However, like any illness during pregnancy, it's wise to inform your healthcare provider. While RSV in pregnant adults is generally not severe, the primary concern is the potential impact on your baby after birth if they are exposed without the protection of maternal antibodies.

Does the RSV vaccine affect breastfeeding?

Current evidence suggests that the RSV vaccine is safe for breastfeeding parents and their infants. While some antibodies are naturally passed through breast milk, the primary and most robust transfer of RSV antibodies occurs across the placenta during pregnancy. Therefore, receiving the vaccine during pregnancy provides the most significant protection for your newborn, and it is compatible with breastfeeding.

Are there any reasons not to get the RSV vaccine while pregnant?

The main reason not to get the RSV vaccine while pregnant would be a severe allergic reaction to any component of the vaccine in the past. Other general contraindications for vaccines, such as a moderate or severe acute illness with or without fever, might temporarily delay vaccination. It's crucial to discuss your full medical history, allergies, and any current health concerns with your healthcare provider to determine if the RSV vaccine is appropriate for you.

How long does the RSV season typically last?

The RSV season varies by geographic location but generally begins in the fall (around September or October) and can last through the winter and into the spring (often until March or April). The peak of RSV activity typically occurs in the colder months, from December to February. Your local health authorities and healthcare providers will be able to provide specific information on the current RSV activity in your community.

When to see a doctor or specialist

While the RSV vaccine is a powerful tool to protect your baby, it's always important to know when to seek medical attention for yourself or your newborn. If you experience any severe or concerning symptoms after receiving the vaccine, such as signs of a serious allergic reaction (difficulty breathing, swelling of the face or throat, hives all over the body), seek emergency medical care immediately.

For your baby, even with vaccination, it's crucial to be vigilant for signs of respiratory distress, especially during RSV season. Call your pediatrician immediately or seek emergency care if your baby:

• Has difficulty breathing, including rapid, shallow breathing or visible retractions (skin pulling in around the ribs or neck).
• Shows signs of bluish lips or skin.
• Is lethargic, unusually sleepy, or difficult to wake.
• Has a persistent cough that is worsening.
• Is not feeding well or showing signs of dehydration (fewer wet diapers).
• Develops a high fever (especially if under 3 months old).

Your OB/GYN can discuss the RSV vaccine with you during your prenatal appointments. For your baby's health post-birth, your pediatrician will be your primary point of contact for any concerns about RSV or other respiratory illnesses.

Please remember that this article is for informational purposes only and does not constitute medical advice. Always consult with your healthcare provider for personalized medical guidance and treatment decisions.

References

1. Centers for Disease Control and Prevention (CDC). RSV During Pregnancy.
   https://www.cdc.gov/rsv/high-risk/pregnant-people.html
2. U.S. Food and Drug Administration (FDA). FDA Approves First RSV Vaccine for Pregnant Individuals to Prevent RSV in Infants. (August 21, 2023).
   https://www.fda.gov/news-events/press-announcements/fda-approves-first-rsv-vaccine-pregnant-individuals-prevent-rsv-infants
3. American College of Obstetricians and Gynecologists (ACOG). RSV Vaccination for Pregnant Individuals. (October 2023).
   https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2023/10/rsv-vaccination-for-pregnant-individuals
4. Hammitt LL, et al. Respiratory Syncytial Virus Vaccine in Pregnant Women and Efficacy in Infants. New England Journal of Medicine. 2023 Apr 20;388(16):1451-1464.
5. Advisory Committee on Immunization Practices (ACIP). Use of Respiratory Syncytial Virus (RSV) Vaccine in Pregnant Individuals: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023–2024. (October 2023).
   https://www.cdc.gov/mmwr/volumes/72/wr/mm7240a4.htm
6. World Health Organization (WHO). Respiratory Syncytial Virus (RSV) vaccines.
   https://www.who.int/teams/immunization-vaccines-and-biologicals/diseases/respiratory-syncytial-virus-vaccines